Elizabeth M Bruckheimer

US Patent:

20050175616, Aug 11, 2005

Filed:

May 26, 2004

Appl. No.:

10/854326

Inventors:

Peter Kiener - Potomac MD, US
Solomon Langermann - Baltimore MD, US
Michael Kinch - Laytonsville MD, US
Elizabeth Bruckheimer - Rockville MD, US

International Classification:

A61K039/395
C07K016/30

US Classification:

424155100, 530388800

Abstract:

The present invention relates to the use of antitumor compositions capable of inhibiting PCDGF biological activity for the treatment of cancers. In particular the present invention relates to the use of PCDGF antagonist, e.g., antibodies that prevent PCDGF from binding its receptor, Rse (also referred to as “Sky” and “Tyro3”).

US Patent:

20050281783, Dec 22, 2005

Filed:

Oct 15, 2004

Appl. No.:

10/966483

Inventors:

Michael Kinch - Laytonsville MD, US
Peter Kiener - Potomac MD, US
Elizabeth Bruckheimer - Rockville MD, US
Thomas Dubensky - Piedmont CA, US
David Cook - Lafayette CA, US

International Classification:

A61K048/00
C12N001/21

US Classification:

424093200, 435252300

Abstract:

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer and cancers of T cell origin, and hyperproliferative diseases involving EphA2-expressing cells. The methods of the invention entail the use of a -based EphA2 vaccine. The invention also provides pharmaceutical compositions comprising one or more -based vaccines of the invention either alone or in combination with one or more other agents useful for cancer therapy. In certain aspects of the invention, the methods entail eliciting both CD4 and CD8 T-cell responses against EphA2 and/or EphA2-expressing cells.

US Patent:

20060002895, Jan 5, 2006

Filed:

May 31, 2005

Appl. No.:

11/141678

Inventors:

Timothy McDonnell - Houston TX, US
Stephen Swisher - Fresno TX, US
Bingliang Fang - Houston TX, US
Elizabeth Bruckheimer - Houston TX, US
Mona Sarkiss - Houston TX, US
Lin Ji - Sugar Land TX, US
Jack Roth - Houston TX, US

International Classification:

A61K 48/00
A61K 38/16
A61K 31/704
A61K 31/7048

US Classification:

424093200, 514008000, 514027000, 514034000, 514044000, 514109000, 514410000, 514283000, 514269000

Abstract:

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.

US Patent:

20080044413, Feb 21, 2008

Filed:

Dec 21, 2006

Appl. No.:

11/645290

Inventors:

Scott Hammond - Olney MD, US
Peter Kiener - Potomac MD, US
Elizabeth Bruckheimer - Rockville MD, US
Michael Kinch - Laytonsville MD, US
Shannon Roff - Eldersburg MD, US
Ralf Lutterbuese - Neuried, DE
Petra Lutterbuese - Neuried, DE
Bernd Schlereth - Germering, DE
Patrick Baeuerle - Gauting, DE
Peter Kufer - Moosburg, DE

International Classification:

A61K 39/395
A61P 31/00
A61P 35/00
A61P 43/00
C07K 16/28

US Classification:

424135100, 530387300

Abstract:

The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2-BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents.

US Patent:

6899870, May 31, 2005

Filed:

Mar 11, 1999

Appl. No.:

09/266465

Inventors:

Timothy J. McDonnell - Houston TX, US
Stephen G. Swisher - Fresno TX, US
Bingliang Fang - Houston TX, US
Elizabeth M. Bruckheimer - Houston TX, US
Mona G. Sarkiss - Houston TX, US
Lin Ji - SugarLand TX, US
Jack A. Roth - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K048/00
C12N015/861
C12N015/63
C07H021/04

US Classification:

424 932, 424 931, 424 936, 4353201, 435 691, 435455, 435456, 435457, 536 231, 536 232, 536 234, 536 235, 536 241

Abstract:

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.